Comparative Pharmacology
Head-to-head clinical analysis: AIRSUPRA versus BUDESONIDE INHALED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AIRSUPRA versus BUDESONIDE INHALED.
AIRSUPRA vs Budesonide (Inhaled)
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AIRSUPRA is a fixed-dose combination of albuterol (a short-acting beta2-agonist) and budesonide (an inhaled corticosteroid). Albuterol relaxes bronchial smooth muscle via beta2-adrenergic receptor activation, increasing cAMP and causing bronchodilation. Budesonide reduces airway inflammation by binding to glucocorticoid receptors, modulating gene transcription to suppress inflammatory mediators.
Budesonide is a glucocorticoid receptor agonist that binds to the glucocorticoid receptor, leading to inhibition of inflammatory mediators such as cytokines and chemokines, and suppression of airway inflammation.
2 inhalations (albuterol 180 mcg / budesonide 160 mcg) orally inhaled twice daily (morning and evening), maximum 2 inhalations twice daily.
200-800 mcg twice daily via inhalation. Maximum 1600 mcg/day.
None Documented
None Documented
Budesonide: 2-3 hours; formoterol: 10-14 hours; clinical context: steady state achieved within days for both
Terminal elimination half-life is 2-3 hours in adults, reflecting rapid clearance. Clinical context: duration of anti-inflammatory effect may exceed half-life due to receptor binding.
Budesonide: ~60% renal as metabolites, ~40% fecal; formoterol: ~60% renal, ~40% fecal
Primarily hepatic metabolism via CYP3A4; metabolites are excreted in urine (~60%) and feces (~40%). Less than 10% of unchanged drug is recovered in urine.
Category C
Category A/B
Inhaled Corticosteroid/SABA Combination
Inhaled Corticosteroid